Kimberly-Clark CEO Mike Hsu discussed his company's $48.7 billion acquisition of Kenvue in a Monday interview with CNBC's Jim Cramer.
Monday - Friday, 6:00 - 7:00 PM ET
In this article
Kimberly-Clark
CEO Mike Hsu told CNBC’s Jim Cramer that his company’s planned acquisition of Tylenol maker Kenvue
will create value for shareholders, even as the the pain reliever is scrutinized by the Trump administration.
Kenvue's shareholders will receive $3.50 per share and 0.15 Kimberly-Clark shares for each Kenvue share held.
The combined company would bring together brands like Huggies and Kleenex with the likes of Band-Aid and Tylenol.
The deal will unite two giants in the over-the-counter health business, bringing together brands like Kleenex and Benadryl.
Kimberly-Clark, il colosso a cui fanno capo i Kleenex e gli Huggies, ha raggiunto un accordo per acquistare Kenvue, la società…
Kimberly-Clark, il colosso a cui fanno capo i Kleenex e gli Huggies, ha raggiunto un accordo per acquistare Kenvue, la società…
The deal has analysts puzzled, as the US maker of Tylenol has seen sales dip after the White House linked it to autism.
Kimberly-Clark buys Tylenol-maker Kenvue in more than $40bn deal
Kimberly-Clark acquista produttore Kenvue per 40 miliardi - Ultima ora - Ansa.it
Kimberly-Clark acquista produttore Kenvue per 40 miliardi - Notizie - Ansa.it
Kimberly-Clark to buy Tylenol maker Kenvue for $40bn
Kimberly-Clark to buy Kenvue, maker of Tylenol, in $48 billion deal
Huggies Maker Buys Kenvue (Tylenol Maker) For $48 Billion
Kimberly-Clark agrees to purchase Kenvue for $48.7B - UPI.com
El dueño de Kleenex compra la empresa de Tylenol y Neutrógena por casi 35.000 millones
Kimberly-Clark swoops on Tylenol maker Kenvue as US deal spree accelerates
